Table 1_Anti-trapping scaffold protein: significance in cancer cell innate immune signaling and opportunities for immunotherapy.xlsx

Recently, Shahi et al. demonstrated that XRCC1 deficiency combined with pharmacological inhibition of Ataxia-Telangiectasia Mutated (ATM) induces mitotic failure, resulting in the accumulation of cytosolic DNA and activation of cancer cell-intrinsic innate immune signaling. Notably, this response was associated with increased PD-L1 expression, which may contribute to adaptive immune resistance. Collectively, these findings suggest that XRCC1 deficiency can promote cancer-cell-intrinsic molecular features associated with innate immune activation.

This may represent a therapeutic vulnerability that warrants further evaluation in gastric cancer, particularly in studies combining DNA damage response (DDR) inhibition with immunotherapy.</p>